...
机译:CYP19A1基因的Rs1008805多态性与激素治疗在第I-II期和可操作阶段III乳腺癌中的疗效相关
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Inst Food &
Drug Control Hangzhou 310052 Zhejiang Peoples R China;
Zhejiang Tradit Chinese Med Univ Affiliated Hosp 1 Dept Med Oncol Hangzhou 310006 Zhejiang;
Zhejiang Canc Hosp Clin Lab Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Canc Res Inst Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Tradit Chinese Med Univ Affiliated Hosp 1 Dept Med Oncol Hangzhou 310006 Zhejiang;
Zhejiang Canc Hosp Canc Res Inst Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
Zhejiang Canc Hosp Dept Med Oncol 38 Guangji Rd Hangzhou 310022 Zhejiang Peoples R China;
breast cancer; aromatase; cytochrome P450 19A1; polymorphisms; predictive role;
机译:CYP19A1基因的Rs1008805多态性与激素治疗在第I-II期和可操作阶段III乳腺癌中的疗效相关
机译:日常辅助化疗的剂量变化和方案修改会影响台湾地区I-II期和可手术III期乳腺癌患者的生存率。
机译:Ⅱ期和Ⅲ期可手术乳腺癌的短期强化新辅助化疗可提高10年生存率
机译:细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
机译:人群中的血清维生素D,维生素D途径的遗传多态性和肌肉减少症与乳腺癌幸存者的总体死亡率和乳腺癌特异性死亡率之间的关联。
机译:CYP19A1基因的Rs1008805多态性与激素治疗I–II期和可手术III期乳腺癌的疗效相关
机译:CYP19A1基因的RS1008805多态性与阶段I-II和可操作阶段III乳腺癌中激素治疗的疗效有关
机译:运动训练对可手术乳腺癌肿瘤血管的影响及对新辅助治疗的反应:I-II期研究(理念奖)